Market closed
Cidara Therapeutics/$CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
69
Website
CDTX Metrics
BasicAdvanced
$252M
-
-$26.75
-
-
Price and volume
Market cap
$252M
52-week high
$28.42
52-week low
$10.00
Average daily volume
100K
Financial strength
Current ratio
4.253
Quick ratio
3.865
Long term debt to equity
1.184
Total debt to equity
2.19
Management effectiveness
Return on assets (TTM)
-40.46%
Return on equity (TTM)
-219.59%
Valuation
Price to revenue (TTM)
114.542
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-0.827
Growth
Revenue change (TTM)
-94.52%
Earnings per share change (TTM)
409.88%
3-year revenue growth (CAGR)
-70.48%
3-year earnings per share growth (CAGR)
18.19%
What the Analysts think about CDTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
CDTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CDTX News
AllArticlesVideos
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·1 week ago
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
GlobeNewsWire·3 weeks ago
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $252M as of March 14, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of March 14, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) does not currently have a Beta indicator.